{"id":"betamethasone-dipropionate","rwe":[],"_fda":{"id":"3fb723a8-70e1-d700-e063-6294a90a53c5","set_id":"000ae256-a337-4903-845b-003777a4efa8","openfda":{"unii":["826Y60901U"],"route":["TOPICAL"],"rxcui":["848176"],"spl_id":["3fb723a8-70e1-d700-e063-6294a90a53c5"],"brand_name":["Betamethasone Dipropionate"],"spl_set_id":["000ae256-a337-4903-845b-003777a4efa8"],"package_ndc":["51672-1310-1","51672-1310-2","51672-1310-3"],"product_ndc":["51672-1310"],"generic_name":["BETAMETHASONE DIPROPIONATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["BETAMETHASONE DIPROPIONATE"],"manufacturer_name":["Sun Pharmaceutical Industries, Inc."],"application_number":["ANDA076543"],"is_original_packager":[true]},"version":"8","pregnancy":["8.1 Pregnancy Risk Summary There are no available data on betamethasone dipropionate cream (augmented) use in pregnant women to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Observational studies suggest an increased risk of low birthweight infants with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. Advise pregnant women that betamethasone dipropionate cream (augmented) may increase the risk of having a low birthweight infant and to use betamethasone dipropionate cream (augmented) on the smallest area of skin and for the shortest duration possible. In animal reproduction studies, increased malformations, including umbilical hernias, cephalocele, and cleft palate, were observed after intramuscular administration of betamethasone dipropionate to pregnant rabbits. The available data do not allow the calculation of relevant comparisons between the systemic exposure of betamethasone dipropionate in animal studies to the systemic exposure that would be expected in humans after topical use of betamethasone dipropionate cream (augmented) (see Data ) . The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Betamethasone dipropionate has been shown to cause malformations in rabbits when given by the intramuscular route at doses of 0.05 mg/kg. The abnormalities observed included umbilical hernias, cephalocele, and cleft palate."],"description":["11 DESCRIPTION Betamethasone dipropionate cream USP (augmented), 0.05% contains betamethasone dipropionate USP, a synthetic adrenocorticosteroid, for topical use in a cream base. Betamethasone, an analog of prednisolone, has a high degree of corticosteroid activity and a slight degree of mineralocorticoid activity. Betamethasone dipropionate is the 17,21-dipropionate ester of betamethasone. Chemically, betamethasone dipropionate is 9-fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate, with the empirical formula C 28 H 37 FO 7 , a molecular weight of 504.6, and the following structural formula: Betamethasone dipropionate is a white to creamy white, odorless crystalline powder, insoluble in water. Each gram of betamethasone dipropionate cream USP (augmented), 0.05% contains: 0.64 mg betamethasone dipropionate USP (equivalent to 0.5 mg betamethasone) in a white cream base of carbomer homopolymer type C, ceteareth-30, chlorocresol, cyclomethicone, glyceryl oleate, propylene glycol, purified water, sodium hydroxide, sorbitol solution, white petrolatum and white wax. Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Betamethasone dipropionate cream USP (augmented), 0.05% is a white cream supplied in 15 g (NDC 51672-1310-1), 30 g (NDC 51672-1310-2) and 50 g (NDC 51672-1310-3) tubes. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from freezing."],"geriatric_use":["8.5 Geriatric Use Clinical trials of betamethasone dipropionate cream (augmented) included 104 subjects who were 65 years of age and over and 8 subjects who were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. However, greater sensitivity of some older individuals cannot be ruled out."],"pediatric_use":["8.4 Pediatric Use Use of betamethasone dipropionate cream (augmented) in pediatric patients younger than 13 years of age is not recommended due to the potential for HPA axis suppression [see Warnings and Precautions (5.1) ] . In an open-label HPA axis safety trial in subjects 3 months to 12 years of age with atopic dermatitis, betamethasone dipropionate cream (augmented), 0.05% was applied twice daily for 2 to 3 weeks over a mean body surface area of 58% (range 35% to 95%). In 19 of 60 (32%) evaluable subjects, adrenal suppression was indicated by either a ≤5 mcg/dL pre-stimulation cortisol, or a cosyntropin post-stimulation cortisol ≤18 mcg/dL and/or an increase of <7 mcg/dL from the baseline cortisol. Out of the 19 subjects with HPA axis suppression, 4 subjects were tested 2 weeks after discontinuation of betamethasone dipropionate cream (augmented), and 3 of the 4 (75%) had complete recovery of HPA axis function. The proportion of subjects with adrenal suppression in this trial was progressively greater, the younger the age group. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of systemic toxicity when treated with topical drugs. They are, therefore, also at greater risk of HPA axis suppression and adrenal insufficiency upon the use of topical corticosteroids. Rare systemic effects such as Cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients, especially those with prolonged exposure to large doses of high potency topical corticosteroids. Local adverse reactions including skin atrophy have also been reported with use of topical corticosteroids in pediatric patients. Avoid use of betamethasone dipropionate cream (augmented) in the treatment of diaper dermatitis."],"effective_time":"20250926","clinical_studies":["14 CLINICAL STUDIES The safety and efficacy of betamethasone dipropionate cream (augmented) for the treatment of corticosteroid-responsive dermatoses have been established in two randomized and active controlled trials in subjects with chronic plaque psoriasis. A total of 81 subjects who received betamethasone dipropionate cream (augmented) were included in these trials. These trials evaluated betamethasone dipropionate cream (augmented) applied once or twice daily for 14 and 21 days, respectively, on bilateral paired psoriatic lesions. Betamethasone dipropionate cream (augmented) was shown to be effective in relieving the signs and symptoms of chronic plaque psoriasis."],"pharmacodynamics":["12.2 Pharmacodynamics Vasoconstrictor Assay Trials performed with betamethasone dipropionate cream (augmented), 0.05% indicate that it is in the high range of potency as demonstrated in vasoconstrictor trials in healthy subjects when compared with other topical corticosteroids. However, similar blanching scores do not necessarily imply therapeutic equivalence."],"pharmacokinetics":["12.3 Pharmacokinetics No pharmacokinetics trials have been conducted with betamethasone dipropionate cream (augmented), 0.05%. The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed through normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids [see Dosage and Administration (2) ] . Once absorbed through the skin, topical corticosteroids enter pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees, are metabolized primarily in the liver, and excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile."],"adverse_reactions":["6 ADVERSE REACTIONS The most common adverse reaction reported in 0.4% of adult patients is stinging. ( 6.1 ) The most common adverse reactions reported in 10% of pediatric patients are signs of skin atrophy, telangiectasia, bruising, shininess. ( 6.1 , 8.4 ) To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc., at 1-866-923-4914 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In controlled clinical trials, involving 242 adult subjects, the adverse reaction associated with the use of betamethasone dipropionate cream (augmented) reported at a frequency of 0.4% was stinging. It occurred in 1 subject. In a controlled clinical trial involving 67 pediatric subjects from 3 months to 12 years of age, the adverse reactions associated with the use of betamethasone dipropionate cream (augmented) occurred in 7 of 67 (10%) subjects. Reported reactions included signs of skin atrophy (telangiectasia, bruising, shininess). 6.2 Postmarketing Experience Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Postmarketing reports for local adverse reactions to topical corticosteroids may also include: burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, hypertrichosis, skin atrophy, striae, and miliaria. Hypersensitivity reactions, consisting of predominantly skin signs and symptoms, e.g., contact dermatitis, pruritus, bullous dermatitis, and erythematous rash have been reported. Ophthalmic adverse reactions of cataracts, glaucoma, increased intraocular pressure, and central serous chorioretinopathy have been reported with the use of topical corticosteroids, including topical betamethasone products."],"contraindications":["4 CONTRAINDICATIONS Betamethasone dipropionate cream (augmented), is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation. Hypersensitivity to any component of this medicine. ( 4 )"],"mechanism_of_action":["12.1 Mechanism of Action Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action of betamethasone dipropionate cream (augmented) in corticosteroid responsive dermatoses is unknown."],"storage_and_handling":["Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from freezing."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action of betamethasone dipropionate cream (augmented) in corticosteroid responsive dermatoses is unknown. 12.2 Pharmacodynamics Vasoconstrictor Assay Trials performed with betamethasone dipropionate cream (augmented), 0.05% indicate that it is in the high range of potency as demonstrated in vasoconstrictor trials in healthy subjects when compared with other topical corticosteroids. However, similar blanching scores do not necessarily imply therapeutic equivalence. 12.3 Pharmacokinetics No pharmacokinetics trials have been conducted with betamethasone dipropionate cream (augmented), 0.05%. The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed through normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids [see Dosage and Administration (2) ] . Once absorbed through the skin, topical corticosteroids enter pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees, are metabolized primarily in the liver, and excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile."],"indications_and_usage":["1 INDICATIONS AND USAGE Betamethasone dipropionate cream (augmented) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older. Betamethasone dipropionate cream (augmented), 0.05% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age and older. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Effects on endocrine system: Betamethasone dipropionate cream (augmented) can cause reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency during and after withdrawal of treatment. Risk factor(s) include the use of high-potency topical corticosteroids, use over a large surface area or to areas under occlusion, prolonged use, altered skin barrier, liver failure, and use in pediatric patients. Modify use should HPA axis suppression develop. ( 5.1 , 8.4 ) Ophthalmic Adverse Reactions: Betamethasone dipropionate cream (augmented) may increase the risk of cataracts and glaucoma. If visual symptoms occur, consider referral to an ophthalmologist for evaluation. ( 5.2 ) 5.1 Effects on Endocrine System Betamethasone dipropionate cream (augmented) can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. This may occur during treatment or after withdrawal of treatment. Factors that predispose to HPA axis suppression include the use of high-potency steroids, large treatment surface areas, prolonged use, use of occlusive dressings, altered skin barrier, liver failure, and young age. Evaluation for HPA axis suppression may be done by using the adrenocorticotropic hormone (ACTH) stimulation test. Betamethasone dipropionate cream (augmented), 0.05% was applied once daily at 7 grams per day for 1 week to diseased skin, in adult subjects with psoriasis or atopic dermatitis, to study its effects on the HPA axis. The results suggested that the drug lowered adrenal corticosteroid secretion, although plasma cortisol levels did not go below the lower limit of the normal range. In an open-label pediatric trial of 60 evaluable subjects (3 months to 12 years of age), 19 subjects showed evidence of HPA axis suppression. Four (4) subjects were tested 2 weeks after discontinuation of betamethasone dipropionate cream (augmented), 0.05%, and 3 of the 4 (75%) had complete recovery of HPA axis function. The proportion of subjects with adrenal suppression in this trial was progressively greater, the younger the age group. If HPA axis suppression is documented, gradually withdraw the drug, reduce the frequency of application, or substitute with a less potent corticosteroid. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Cushing's syndrome and hyperglycemia may also occur with topical corticosteroids. These events are rare and generally occur after prolonged exposure to excessively large doses, especially of high-potency topical corticosteroids. Pediatric patients may be more susceptible to systemic toxicity due to their larger skin surface to body mass ratios [see Use in Specific Populations (8.4) ]. 5.2 Ophthalmic Adverse Reactions Use of topical corticosteroids, including betamethasone dipropionate cream (augmented), may increase the risk of posterior subcapsular cataracts and glaucoma. Cataracts and glaucoma have been reported postmarketing with the use of topical corticosteroid products, including betamethasone dipropionate cream (augmented) [see Adverse Reactions (6.2)] . 5.3 Allergic Contact Dermatitis Allergic contact dermatitis with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation. Such an observation should be corroborated with appropriate diagnostic patch testing. If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential of betamethasone dipropionate. Betamethasone was negative in the bacterial mutagenicity assay (Salmonella typhimurium and Escherichia coli), and in the mammalian cell mutagenicity assay (CHO/HGPRT). It was positive in the in vitro human lymphocyte chromosome aberration assay, and equivocal in the in vivo mouse bone marrow micronucleus assay. Studies in rabbits, mice, and rats using intramuscular doses up to 1, 33, and 2 mg/kg, respectively, resulted in dose-related increases in fetal resorptions in rabbits and mice."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Inform patients of the following: Discontinue therapy when control is achieved, unless directed otherwise by the physician. Use no more than 50 grams per week. Avoid contact with the eyes. Advise patients to report any visual symptoms to their healthcare providers. Avoid use of betamethasone dipropionate cream (augmented) on the face, underarms, or groin areas unless directed by the physician. Do not occlude the treatment area with bandage or other covering, unless directed by the physician. Note that local reactions and skin atrophy are more likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids. Advise a woman to use betamethasone dipropionate cream (augmented) on the smallest area of skin and for the shortest duration possible while pregnant or breastfeeding. Advise breastfeeding women not to apply betamethasone dipropionate cream (augmented) directly to the nipple and areola to avoid direct infant exposure."],"spl_unclassified_section":["Mfd. by: Sun Pharma Canada Inc., Brampton, Ontario, Canada L6T 1C1 Dist. by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512 Revised: December 2025 5264297-0925-01 51"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Apply a thin film of betamethasone dipropionate cream (augmented) to the affected skin areas once or twice daily. Therapy should be discontinued when control is achieved. Betamethasone dipropionate cream (augmented) is a high-potency corticosteroid. Treatment with betamethasone dipropionate cream (augmented) should not exceed 50 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis [see Warnings and Precautions (5.1) ]. Betamethasone dipropionate cream (augmented) should not be used with occlusive dressings unless directed by a physician. Avoid contact with eyes. Wash hands after each application. Avoid use on the face, groin, or axillae, or if skin atrophy is present at the treatment site. Betamethasone dipropionate cream (augmented) is for topical use only. It is not for oral, ophthalmic, or intravaginal use. Apply a thin film to the affected skin areas once or twice daily. ( 2 ) Discontinue therapy when control is achieved. ( 2 ) Use no more than 50 g per week. ( 2 ) Do not use with occlusive dressings unless directed by a physician. ( 2 ) Avoid use on the face, groin, or axillae, or if skin atrophy is present at the treatment site. ( 2 ) Not for oral, ophthalmic, or intravaginal use. ( 2 )"],"spl_product_data_elements":["Betamethasone Dipropionate Betamethasone Dipropionate CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) CETEARETH-30 CHLOROCRESOL CYCLOMETHICONE 5 GLYCERYL OLEATE PROPYLENE GLYCOL WATER SODIUM HYDROXIDE SORBITOL PETROLATUM WHITE WAX BETAMETHASONE DIPROPIONATE BETAMETHASONE"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Cream, 0.05%. Each gram of betamethasone dipropionate cream USP (augmented), 0.05% contains 0.64 mg betamethasone dipropionate (equivalent to 0.5 mg betamethasone) in a white cream base. Cream, 0.05% ( 3 )"],"spl_patient_package_insert":["Patient Information Betamethasone Dipropionate (bay'' ta meth' a sone dye proe' pee oh nate) Cream (Augmented) This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 09/2025 Important information: Betamethasone Dipropionate Cream (Augmented) is for use on skin only . Do not use betamethasone dipropionate cream (augmented) in your eyes, mouth, or vagina. What is Betamethasone Dipropionate Cream (Augmented)? Betamethasone dipropionate cream (augmented) is a prescription corticosteroid medicine used on the skin (topical) for the relief of redness, swelling, heat, pain (inflammation) and itching, caused by certain skin problems in people 13 years of age and older. Betamethasone dipropionate cream (augmented) should not be used in children under 13 years of age. Do not use Betamethasone Dipropionate Cream (Augmented) if you are allergic to betamethasone dipropionate or any of the ingredients in betamethasone dipropionate cream (augmented). See the end of this leaflet for a complete list of ingredients in betamethasone dipropionate cream (augmented). Before using Betamethasone Dipropionate Cream (Augmented), tell your healthcare provider about all of your medical conditions, including if you: have had irritation or other skin reaction to a steroid medicine in the past. have thinning of the skin (atrophy) at the treatment site. have diabetes. have adrenal gland problems. have liver problems. have cataracts or glaucoma. are pregnant or plan to become pregnant. It is not known if betamethasone dipropionate cream (augmented) will harm your unborn baby. If you use betamethasone dipropionate cream (augmented) during pregnancy, use betamethasone dipropionate cream (augmented) on the smallest area of the skin and for the shortest time needed. are breastfeeding or plan to breastfeed. It is not known if betamethasone dipropionate cream (augmented) passes into your breast milk. Breastfeeding women should use betamethasone dipropionate cream (augmented) on the smallest area of the skin and for the shortest time needed. Do not apply betamethasone dipropionate cream (augmented) directly to the nipple and areola to avoid contact with your baby. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take other corticosteroid medicines by mouth or injection or use other products on your skin or scalp that contain corticosteroids. Do not use other products containing a steroid medicine with betamethasone dipropionate cream (augmented) without talking to your healthcare provider first. How should I use Betamethasone Dipropionate Cream (Augmented)? Use betamethasone dipropionate cream (augmented) exactly as your healthcare provider tells you to use it. Apply a thin layer (film) of betamethasone dipropionate cream (augmented) to the affected skin area 1 or 2 times each day. Do not use more than 50 grams of betamethasone dipropionate cream (augmented) in 1 week. Do not bandage, cover, or wrap the treated skin area unless your healthcare provider tells you to. Betamethasone dipropionate cream (augmented) should not be used to treat diaper rash or redness. Avoid using betamethasone dipropionate cream (augmented) on the face, groin, or underarms (armpits) or if thinning of the skin (atrophy) is present at the treatment site. Wash your hands after applying betamethasone dipropionate cream (augmented) unless you are using the medicine to treat your hands. What are the possible side effects of Betamethasone Dipropionate Cream (Augmented)? Betamethasone Dipropionate Cream (Augmented) may cause serious side effects, including: Betamethasone dipropionate cream (augmented) can pass through your skin. Too much betamethasone dipropionate cream (augmented) passing through your skin can cause your adrenal glands to stop working properly. Your healthcare provider may do blood tests to check for adrenal gland problems. Cushing's syndrome , a condition that happens when your body is exposed to too much of the hormone cortisol. High blood sugar (hyperglycemia). Effects on growth and weight in children. Vision problems. Topical corticosteroids including betamethasone dipropionate cream (augmented) may increase your chance of developing cataract(s) and glaucoma. Tell your healthcare provider if you develop blurred vision or other vision problems during treatment with betamethasone dipropionate cream (augmented). Skin problems. Skin problems including, allergic reactions (contact dermatitis) may happen during treatment with betamethasone dipropionate cream (augmented). Stop using betamethasone dipropionate cream (augmented) and tell your healthcare provider if you develop any skin reactions or have problems with healing during treatment with betamethasone dipropionate cream (augmented). Your healthcare provider may do certain blood tests to check for side effects. The most common side effect of betamethasone dipropionate cream (augmented) in adults includes stinging. The most common side effects of betamethasone dipropionate cream (augmented) in children include thinning of the skin (atrophy), tiny red lines or blood vessels showing under the skin (telangiectasia), bruising and shininess. These are not all of the possible side effects of betamethasone dipropionate cream (augmented). Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store Betamethasone Dipropionate Cream (Augmented)? Store betamethasone dipropionate cream (augmented) at room temperature between 68°F to 77°F (20°C to 25°C). Protect from freezing. Keep betamethasone dipropionate cream (augmented) and all medicines out of the reach of children. General information about the safe and effective use of Betamethasone Dipropionate Cream (Augmented). Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use betamethasone dipropionate cream (augmented) for a condition for which it was not prescribed. Do not give betamethasone dipropionate cream (augmented) to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about betamethasone dipropionate cream (augmented) that is written for health professionals. What are the ingredients in Betamethasone Dipropionate Cream (Augmented)? Active ingredient: betamethasone dipropionate Inactive ingredients: carbomer homopolymer type C, ceteareth-30, chlorocresol, cyclomethicone, glyceryl oleate, propylene glycol, purified water, sodium hydroxide, sorbitol solution, white petrolatum and white wax. Manufactured by: Sun Pharma Canada Inc., Brampton, Ontario, Canada L6T 1C1 Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512 Revised: September 2025 5264297-0925-01 51"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no available data on betamethasone dipropionate cream (augmented) use in pregnant women to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Observational studies suggest an increased risk of low birthweight infants with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. Advise pregnant women that betamethasone dipropionate cream (augmented) may increase the risk of having a low birthweight infant and to use betamethasone dipropionate cream (augmented) on the smallest area of skin and for the shortest duration possible. In animal reproduction studies, increased malformations, including umbilical hernias, cephalocele, and cleft palate, were observed after intramuscular administration of betamethasone dipropionate to pregnant rabbits. The available data do not allow the calculation of relevant comparisons between the systemic exposure of betamethasone dipropionate in animal studies to the systemic exposure that would be expected in humans after topical use of betamethasone dipropionate cream (augmented) (see Data ) . The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Betamethasone dipropionate has been shown to cause malformations in rabbits when given by the intramuscular route at doses of 0.05 mg/kg. The abnormalities observed included umbilical hernias, cephalocele, and cleft palate. 8.2 Lactation Risk Summary There are no data regarding the excretion of betamethasone dipropionate in breast milk, the effects on the breastfed infant, or the effects on milk production after topical application of betamethasone dipropionate cream (augmented) to women who are breastfeeding. It is possible that topical administration of large amounts of betamethasone dipropionate could result in sufficient systemic absorption to produce detectable quantities in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for betamethasone dipropionate cream (augmented) and any potential adverse effects on the breastfed infant from betamethasone dipropionate cream (augmented) or from the underlying maternal condition. Clinical Considerations To minimize potential exposure to the breastfed infant via breast milk, use betamethasone dipropionate cream (augmented) on the smallest area of skin and for the shortest duration possible while breastfeeding. Advise breastfeeding women not to apply betamethasone dipropionate cream (augmented) directly to the nipple and areola to avoid direct infant exposure [see Use in Specific Populations (8.4) ] . 8.4 Pediatric Use Use of betamethasone dipropionate cream (augmented) in pediatric patients younger than 13 years of age is not recommended due to the potential for HPA axis suppression [see Warnings and Precautions (5.1) ] . In an open-label HPA axis safety trial in subjects 3 months to 12 years of age with atopic dermatitis, betamethasone dipropionate cream (augmented), 0.05% was applied twice daily for 2 to 3 weeks over a mean body surface area of 58% (range 35% to 95%). In 19 of 60 (32%) evaluable subjects, adrenal suppression was indicated by either a ≤5 mcg/dL pre-stimulation cortisol, or a cosyntropin post-stimulation cortisol ≤18 mcg/dL and/or an increase of <7 mcg/dL from the baseline cortisol. Out of the 19 subjects with HPA axis suppression, 4 subjects were tested 2 weeks after discontinuation of betamethasone dipropionate cream (augmented), and 3 of the 4 (75%) had complete recovery of HPA axis function. The proportion of subjects with adrenal suppression in this trial was progressively greater, the younger the age group. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of systemic toxicity when treated with topical drugs. They are, therefore, also at greater risk of HPA axis suppression and adrenal insufficiency upon the use of topical corticosteroids. Rare systemic effects such as Cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients, especially those with prolonged exposure to large doses of high potency topical corticosteroids. Local adverse reactions including skin atrophy have also been reported with use of topical corticosteroids in pediatric patients. Avoid use of betamethasone dipropionate cream (augmented) in the treatment of diaper dermatitis. 8.5 Geriatric Use Clinical trials of betamethasone dipropionate cream (augmented) included 104 subjects who were 65 years of age and over and 8 subjects who were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. However, greater sensitivity of some older individuals cannot be ruled out."],"spl_patient_package_insert_table":["<table width=\"100%\"><col align=\"left\" valign=\"middle\" width=\"85%\"/><col align=\"left\" valign=\"middle\" width=\"15%\"/><thead><tr><th align=\"center\" colspan=\"2\" styleCode=\"Lrule Rrule\">Patient Information   Betamethasone Dipropionate   (bay&apos;&apos; ta meth&apos; a sone dye proe&apos; pee oh nate)   Cream (Augmented) </th></tr></thead><tfoot><tr><td align=\"left\">This Patient Information has been approved by the U.S. Food and Drug Administration.</td><td align=\"left\">Revised: 09/2025</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td colspan=\"2\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Important information: Betamethasone Dipropionate Cream (Augmented) is for use on skin only</content>. Do not use betamethasone dipropionate cream (augmented) in your eyes, mouth, or vagina. </td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">What is Betamethasone Dipropionate Cream (Augmented)?</content></td></tr><tr styleCode=\"Botrule\"><td colspan=\"2\" styleCode=\"Lrule Rrule\">Betamethasone dipropionate cream (augmented) is a prescription corticosteroid medicine used on the skin (topical) for the relief of redness, swelling, heat, pain (inflammation) and itching, caused by certain skin problems in people 13 years of age and older. <list listType=\"unordered\" styleCode=\"Disc\"><item>Betamethasone dipropionate cream (augmented) should not be used in children under 13 years of age.</item></list></td></tr><tr styleCode=\"Botrule\"><td colspan=\"2\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Do not use Betamethasone Dipropionate Cream (Augmented) if you</content>are allergic to betamethasone dipropionate or any of the ingredients in betamethasone dipropionate cream (augmented). See the end of this leaflet for a complete list of ingredients in betamethasone dipropionate cream (augmented). </td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Before using Betamethasone Dipropionate Cream (Augmented), tell your healthcare provider about all of your medical conditions, including if you:</content><list listType=\"unordered\" styleCode=\"Disc\"><item>have had irritation or other skin reaction to a steroid medicine in the past.</item><item>have thinning of the skin (atrophy) at the treatment site.</item><item>have diabetes.</item><item>have adrenal gland problems.</item><item>have liver problems.</item><item>have cataracts or glaucoma.</item><item>are pregnant or plan to become pregnant. It is not known if betamethasone dipropionate cream (augmented) will harm your unborn baby. If you use betamethasone dipropionate cream (augmented) during pregnancy, use betamethasone dipropionate cream (augmented) on the smallest area of the skin and for the shortest time needed.</item><item>are breastfeeding or plan to breastfeed. It is not known if betamethasone dipropionate cream (augmented) passes into your breast milk. Breastfeeding women should use betamethasone dipropionate cream (augmented) on the smallest area of the skin and for the shortest time needed. Do not apply betamethasone dipropionate cream (augmented) directly to the nipple and areola to avoid contact with your baby.</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Tell your healthcare provider about all the medicines you take,</content>including prescription and over-the-counter medicines, vitamins, and herbal supplements. </td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Especially</content>tell your healthcare provider if you take other corticosteroid medicines by mouth or injection or use other products on your skin or scalp that contain corticosteroids. </td></tr><tr styleCode=\"Botrule\"><td colspan=\"2\" styleCode=\"Lrule Rrule\">Do not use other products containing a steroid medicine with betamethasone dipropionate cream (augmented) without talking to your healthcare provider first.</td></tr><tr styleCode=\"Botrule\"><td colspan=\"2\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">How should I use Betamethasone Dipropionate Cream (Augmented)?</content><list listType=\"unordered\" styleCode=\"Disc\"><item>Use betamethasone dipropionate cream (augmented) exactly as your healthcare provider tells you to use it.</item><item>Apply a thin layer (film) of betamethasone dipropionate cream (augmented) to the affected skin area 1 or 2 times each day. Do not use more than 50 grams of betamethasone dipropionate cream (augmented) in 1 week.</item><item>Do not bandage, cover, or wrap the treated skin area unless your healthcare provider tells you to.</item><item>Betamethasone dipropionate cream (augmented) should not be used to treat diaper rash or redness.</item><item>Avoid using betamethasone dipropionate cream (augmented) on the face, groin, or underarms (armpits) or if thinning of the skin (atrophy) is present at the treatment site.</item><item>Wash your hands after applying betamethasone dipropionate cream (augmented) unless you are using the medicine to treat your hands.</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">What are the possible side effects of Betamethasone Dipropionate Cream (Augmented)?</content></td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Betamethasone Dipropionate Cream (Augmented) may cause serious side effects, including:</content><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"bold\">Betamethasone dipropionate cream (augmented) can pass through your skin.</content>Too much betamethasone dipropionate cream (augmented) passing through your skin can cause your adrenal glands to stop working properly. Your healthcare provider may do blood tests to check for adrenal gland problems. </item><item><content styleCode=\"bold\">Cushing&apos;s syndrome</content>, a condition that happens when your body is exposed to too much of the hormone cortisol. </item><item><content styleCode=\"bold\">High blood sugar</content>(hyperglycemia). </item><item><content styleCode=\"bold\">Effects on growth and weight in children.</content></item><item><content styleCode=\"bold\">Vision problems.</content>Topical corticosteroids including betamethasone dipropionate cream (augmented) may increase your chance of developing cataract(s) and glaucoma. Tell your healthcare provider if you develop blurred vision or other vision problems during treatment with betamethasone dipropionate cream (augmented). </item><item><content styleCode=\"bold\">Skin problems.</content>Skin problems including, allergic reactions (contact dermatitis) may happen during treatment with betamethasone dipropionate cream (augmented). Stop using betamethasone dipropionate cream (augmented) and tell your healthcare provider if you develop any skin reactions or have problems with healing during treatment with betamethasone dipropionate cream (augmented). </item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\">Your healthcare provider may do certain blood tests to check for side effects.</td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">The most common side effect of betamethasone dipropionate cream (augmented) in adults includes</content>stinging. </td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">The most common side effects of betamethasone dipropionate cream (augmented) in children include</content>thinning of the skin (atrophy), tiny red lines or blood vessels showing under the skin (telangiectasia), bruising and shininess. </td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\">These are not all of the possible side effects of betamethasone dipropionate cream (augmented).</td></tr><tr styleCode=\"Botrule\"><td colspan=\"2\" styleCode=\"Lrule Rrule\">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td></tr><tr styleCode=\"Botrule\"><td colspan=\"2\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">How should I store Betamethasone Dipropionate Cream (Augmented)?</content><list listType=\"unordered\" styleCode=\"Disc\"><item>Store betamethasone dipropionate cream (augmented) at room temperature between 68&#xB0;F to 77&#xB0;F (20&#xB0;C to 25&#xB0;C). Protect from freezing.</item><item><content styleCode=\"bold\">Keep betamethasone dipropionate cream (augmented) and all medicines out of the reach of children.</content></item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">General information about the safe and effective use of Betamethasone Dipropionate Cream (Augmented).</content></td></tr><tr styleCode=\"Botrule\"><td colspan=\"2\" styleCode=\"Lrule Rrule\">Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use betamethasone dipropionate cream (augmented) for a condition for which it was not prescribed. Do not give betamethasone dipropionate cream (augmented) to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about betamethasone dipropionate cream (augmented) that is written for health professionals.</td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">What are the ingredients in Betamethasone Dipropionate Cream (Augmented)?</content></td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Active ingredient:</content>betamethasone dipropionate </td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Inactive ingredients:</content>carbomer homopolymer type C, ceteareth-30, chlorocresol, cyclomethicone, glyceryl oleate, propylene glycol, purified water, sodium hydroxide, sorbitol solution, white petrolatum and white wax. </td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\">Manufactured by: Sun Pharma Canada Inc., Brampton, Ontario, Canada L6T 1C1</td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\">Distributed by: <content styleCode=\"bold\">Sun Pharmaceutical Industries, Inc.,</content>Cranbury, NJ 08512 </td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\">Revised: September 2025 5264297-0925-01 51</td></tr></tbody></table>"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 15 g Tube Carton NDC 51672-1310-1 15 g Betamethasone Dipropionate Cream USP (Augmented), 0.05%* *Strength expressed as betamethasone FOR DERMATOLOGIC USE ONLY. NOT FOR OPHTHALMIC USE. Rx only Keep this and all medications out of the reach of children. PRINCIPAL DISPLAY PANEL - 15 g Tube Carton SUN label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential of betamethasone dipropionate. Betamethasone was negative in the bacterial mutagenicity assay (Salmonella typhimurium and Escherichia coli), and in the mammalian cell mutagenicity assay (CHO/HGPRT). It was positive in the in vitro human lymphocyte chromosome aberration assay, and equivocal in the in vivo mouse bone marrow micronucleus assay. Studies in rabbits, mice, and rats using intramuscular doses up to 1, 33, and 2 mg/kg, respectively, resulted in dose-related increases in fetal resorptions in rabbits and mice."]},"tags":[{"label":"Corticosteroid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Glucocorticoid receptor","category":"target"},{"label":"NR3C1","category":"gene"},{"label":"Topical","category":"route"},{"label":"Aerosol","category":"form"},{"label":"Cream","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Atopic dermatitis","category":"indication"},{"label":"Contact dermatitis","category":"indication"},{"label":"Discoid lupus erythematosus","category":"indication"},{"label":"Eruption of skin","category":"indication"},{"label":"Granuloma annulare","category":"indication"},{"label":"Lichen simplex chronicus","category":"indication"},{"label":"Schering","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Anti-Asthmatic Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Glucocorticoids","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"},{"label":"Respiratory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"1654 reports"},{"date":"","signal":"PSORIASIS","source":"FDA FAERS","actionTaken":"1087 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"668 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"640 reports"},{"date":"","signal":"PRURITUS","source":"FDA FAERS","actionTaken":"575 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"569 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"533 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"532 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"530 reports"},{"date":"","signal":"MACULAR DEGENERATION","source":"FDA FAERS","actionTaken":"523 reports"}],"commonSideEffects":[{"effect":"Skin atrophy","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Non-facial atrophy","drugRate":"","severity":"common","_validated":false,"_confidence":0.3}],"contraindications":["Adrenal cortical hypofunction","Atrophoderma","Congenital ichthyosis of skin","Disorder of calcium metabolism","Guttate psoriasis","Hypercalcemia","Hypercalciuria","Hypervitaminosis D","Peripheral vascular disease","Pustular psoriasis","Telangiectasia disorder"],"specialPopulations":{"Pregnancy":"There are no available data on DIPROLENE Ointment use in pregnant women to identify drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Observational studies suggest an increased risk of low birthweight infants with the use of greater than 300 grams of potent or very potent topical corticosteroid during pregnancy. Advise pregnant women that DIPROLENE Ointment may increase the risk of having low birthweight infant and to use DIPROLENE Ointment on the smallest area of skin and for the shortest duration possible. In animal reproduction studies, increased malformations, including umbilical hernias, cephalocele, and cleft palate, were observed after intramuscular administration of betamethasone dipropionate to pregnant rabbits. The available data do not allow the calculation of relevant comparisons between the systemic exposure of betamethasone dipropionate in animal studies to the systemic exposure that would be expected in humans after topical use of DIPROLENE Ointment (see Data). The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is to 4% and 15 to 20%, respectively. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Betamethasone dipropionate has been shown to be teratogenic in rabbits when given by the intramuscular route at doses of 0.05 mg/kg. This dose is approximately 0.2-fold the maximum human dose based on mg/m2 comparison. The abnormalities observed included umbilical hernias, cephalocele and cleft palates. Some corticosteroids are known to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Betamethasone dipropionate has been shown to be teratogenic in rabbits when given by the intramuscular route at doses of 0.05 mg/kg. This dose is approximately 0.2-fold the maximum human dose based on mg/m2 comparison. The abnormalities observed included umbilical hernias, cephalocele and cleft palates.","Geriatric use":"Clinical studies of betamethasone dipropionate cream, 0.05% (augmented) included 104 subjects who were 65 years of age and over and subjects who were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. However, greater sensitivity of some older individuals cannot be ruled out.","Paediatric use":"Use of betamethasone dipropionate cream, 0.05% (augmented) in pediatric patients 12 years of age and younger is not recommended. (See CLINICAL PHARMACOLOGY and ADVERSE REACTIONS sections.) In an open-label study, 19 of 60 (32%) evaluable pediatric patients (aged months-12 years old) using betamethasone dipropionate cream, 0.05% (augmented) for treatment of atopic dermatitis demonstrated HPA axis suppression. The proportion of patients with adrenal suppression in this study was progressively higher with increasing age, with 8 of 14 (57%) patients aged 3 to 6 years and 11 of 14 (79%) patients aged 7 to 12 years demonstrating HPA axis suppression. The proportion of patients with adrenal suppression in this study was progressively higher with increasing age, with 8 of 14 (57%) patients aged 3 to 6 years and 11 of 14 (79%) patients aged 7 to 12 years demonstrating HPA axis suppression."}},"trials":[],"aliases":[],"company":"Merck & Co.","patents":[{"type":"Formulation","number":"9775851","applicant":"PRIMUS PHARMACEUTICALS INC","territory":"US","tradeName":"SERNIVO","expiryDate":"2030-08-31"},{"type":"Formulation","number":"9364485","applicant":"PRIMUS PHARMACEUTICALS INC","territory":"US","tradeName":"SERNIVO","expiryDate":"2030-08-31"},{"type":"Formulation","number":"9655907","applicant":"PRIMUS PHARMACEUTICALS INC","territory":"US","tradeName":"SERNIVO","expiryDate":"2030-08-31"},{"type":"Formulation","number":"10179137","applicant":"PRIMUS PHARMACEUTICALS INC","territory":"US","tradeName":"SERNIVO","expiryDate":"2030-08-31"},{"type":"Formulation","number":"9433630","applicant":"PRIMUS PHARMACEUTICALS INC","territory":"US","tradeName":"SERNIVO","expiryDate":"2030-08-31"},{"type":"Formulation","number":"9877974","applicant":"PRIMUS PHARMACEUTICALS INC","territory":"US","tradeName":"SERNIVO","expiryDate":"2030-08-31"},{"type":"Formulation","number":"9439911","applicant":"PRIMUS PHARMACEUTICALS INC","territory":"US","tradeName":"SERNIVO","expiryDate":"2030-08-31"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=BETAMETHASONE DIPROPIONATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:43:43.608895+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:43:43.608809+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:43:49.361482+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:43:42.726991+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BETAMETHASONE DIPROPIONATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:43:50.015650+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:43:40.906485+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:43:40.906516+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:43:51.546200+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3138708/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:43:50.746741+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA076543","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:43:40.906521+00:00"}},"allNames":"diprolene","offLabel":[],"synonyms":["betamethasone dipropionate","diproderm","diprosone"],"timeline":[{"date":"1975-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from SCHERING to Schering"},{"date":"1983-07-27","type":"positive","source":"FDA Orange Book","milestone":"Diprolene approved — EQ 0.05% BASE"},{"date":"1984-06-26","type":"positive","source":"FDA Orange Book","milestone":"Alphatrex approved — EQ 0.05% BASE"},{"date":"1984-09-04","type":"positive","source":"FDA Orange Book","milestone":"Alphatrex approved — EQ 0.05% BASE"},{"date":"1986-01-31","type":"positive","source":"FDA Orange Book","milestone":"Diprolene approved — EQ 0.05% BASE"},{"date":"1987-04-27","type":"positive","source":"FDA Orange Book","milestone":"Diprolene Af approved — EQ 0.05% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"1988-08-01","type":"positive","source":"FDA Orange Book","milestone":"Diprolene approved — EQ 0.05% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"2016-02-05","type":"positive","source":"FDA Orange Book","milestone":"Sernivo approved — EQ 0.05% BASE/SPRAY"},{"date":"2024-04-10","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 21 manufacturers approved"}],"aiSummary":"Diprolene (BETAMETHASONE DIPROPIONATE) is a corticosteroid medication originally developed by SCHERING and currently owned by the same company. It targets the glucocorticoid receptor and is used to treat various skin conditions, including atopic dermatitis, contact dermatitis, and plaque psoriasis. Diprolene is a small molecule corticosteroid that has been FDA-approved since 1975 and is now available as a generic medication. It is off-patent and has multiple generic manufacturers. Key safety considerations include potential skin thinning and increased risk of infections.","brandName":"Diprolene","ecosystem":[{"indication":"Atopic dermatitis","otherDrugs":[{"name":"abrocitinib","slug":"abrocitinib","company":"PFIZER Inc"},{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"}],"globalPrevalence":204050000},{"indication":"Contact dermatitis","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"benzoyl peroxide","slug":"benzoyl-peroxide","company":"Valeant Intl"}],"globalPrevalence":324000000},{"indication":"Discoid lupus erythematosus","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone benzoate","slug":"betamethasone-benzoate","company":"Parke Davis"}],"globalPrevalence":2400000},{"indication":"Eruption of skin","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"benzoyl peroxide","slug":"benzoyl-peroxide","company":"Valeant Intl"}],"globalPrevalence":null},{"indication":"Granuloma annulare","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"benzoyl peroxide","slug":"benzoyl-peroxide","company":"Valeant Intl"}],"globalPrevalence":null},{"indication":"Lichen simplex chronicus","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone benzoate","slug":"betamethasone-benzoate","company":"Parke Davis"}],"globalPrevalence":null},{"indication":"Plaque psoriasis","otherDrugs":[{"name":"adalimumab","slug":"adalimumab","company":"Abbvie Inc"},{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"alefacept","slug":"alefacept","company":"Astellas"},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"}],"globalPrevalence":125000000},{"indication":"Primary cutaneous T-cell lymphoma","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone benzoate","slug":"betamethasone-benzoate","company":"Parke Davis"}],"globalPrevalence":null}],"mechanism":{"target":"Glucocorticoid receptor","novelty":"Follow-on","targets":[{"gene":"NR3C1","source":"DrugCentral","target":"Glucocorticoid receptor","protein":"Glucocorticoid receptor"}],"moaClass":"Corticosteroid Hormone Receptor Agonists","modality":"Small Molecule","drugClass":"Corticosteroid","explanation":"Mechanism of Action. Clotrimazole is an imidazole antifungal agent. Imidazoles inhibit 14--demethylation of lanosterol in fungi by binding to one of the cytochrome P-450 enzymes. This leads to the accumulation of 14--methylsterols and reduced concentrations of ergosterol, sterol essential for normal fungal cytoplasmic membrane. The methylsterols may affect the electron transport system, thereby inhibiting growth of fungi.","oneSentence":"Diprolene works by binding to the glucocorticoid receptor in the skin, which reduces inflammation and suppresses the immune system.","technicalDetail":"Diprolene exerts its effects by binding to the glucocorticoid receptor (GR), a transcription factor that regulates the expression of genes involved in inflammation and immune response. This binding leads to the inhibition of pro-inflammatory gene expression and the induction of anti-inflammatory gene expression, resulting in reduced inflammation and immune activity in the skin.","_target_confidence":0.5},"commercial":{"launchDate":"1975","_launchSource":"DrugCentral (FDA 1975-01-29, SCHERING)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/353","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BETAMETHASONE%20DIPROPIONATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BETAMETHASONE DIPROPIONATE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:59:04.670694","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:43:58.890147+00:00","fieldsConflicting":3,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"alclometasone dipropionate","drugSlug":"alclometasone-dipropionate","fdaApproval":"1982-12-14","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amcinonide","drugSlug":"amcinonide","fdaApproval":"1979-10-18","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"auranofin","drugSlug":"auranofin","fdaApproval":"1985-05-24","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"beclometasone dipropionate","drugSlug":"beclometasone-dipropionate","fdaApproval":"1976-05-12","relationship":"same-target"},{"drugName":"betamethasone","drugSlug":"betamethasone","fdaApproval":"1961-04-17","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"betamethasone acetate","drugSlug":"betamethasone-acetate","fdaApproval":"1965-03-03","relationship":"same-target"},{"drugName":"betamethasone benzoate","drugSlug":"betamethasone-benzoate","fdaApproval":"","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"betamethasone phosphate","drugSlug":"betamethasone-phosphate","fdaApproval":"1965-03-03","relationship":"same-target"},{"drugName":"betamethasone valerate","drugSlug":"betamethasone-valerate","fdaApproval":"1967-09-02","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"budesonide","drugSlug":"budesonide","fdaApproval":"1994-02-14","patentExpiry":"Sep 9, 2036","patentStatus":"Patent protected","relationship":"same-target"}],"genericName":"betamethasone dipropionate","indications":{"approved":[{"name":"Atopic dermatitis","source":"DrugCentral","snomedId":24079001,"regulator":"FDA","eligibility":"Adults and pediatric patients 6 months of age and older","usPrevalence":null,"globalPrevalence":204050000,"prevalenceMethod":"curated","prevalenceSource":"Br J Dermatol, 2023 (PMID:37705227)"},{"name":"Contact dermatitis","source":"DrugCentral","snomedId":40275004,"regulator":"FDA","eligibility":"Adults and pediatric patients 6 months of age and older","usPrevalence":null,"globalPrevalence":324000000,"prevalenceMethod":"curated","prevalenceSource":"Contact Dermatitis, 2025 (PMID:40107276)"},{"name":"Discoid lupus erythematosus","source":"DrugCentral","snomedId":200938002,"regulator":"FDA","eligibility":"Not specified","usPrevalence":null,"globalPrevalence":2400000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (ORPHANET)"},{"name":"Eruption of skin","source":"DrugCentral","snomedId":271807003,"regulator":"FDA","eligibility":"Not specified"},{"name":"Granuloma annulare","source":"DrugCentral","snomedId":65508009,"regulator":"FDA","eligibility":"Not specified"},{"name":"Lichen simplex chronicus","source":"DrugCentral","snomedId":53891004,"regulator":"FDA","eligibility":"Not specified"},{"name":"Plaque psoriasis","source":"DrugCentral","snomedId":200965009,"regulator":"FDA","eligibility":"Adults and pediatric patients 6 months of age and older","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Primary cutaneous T-cell lymphoma","source":"DrugCentral","snomedId":400122007,"regulator":"FDA","eligibility":"Not specified"},{"name":"Pruritus ani","source":"DrugCentral","snomedId":90446007,"regulator":"FDA","eligibility":"Not specified"},{"name":"Pruritus of genital organs","source":"DrugCentral","snomedId":267802000,"regulator":"FDA","eligibility":"Not specified"},{"name":"Scalp psoriasis","source":"DrugCentral","snomedId":238608008,"regulator":"FDA","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Seborrheic dermatitis","source":"DrugCentral","snomedId":50563003,"regulator":"FDA"},{"name":"Tinea corporis","source":"DrugCentral","snomedId":84849002,"regulator":"FDA"},{"name":"Tinea cruris","source":"DrugCentral","snomedId":399029005,"regulator":"FDA"},{"name":"Tinea pedis","source":"DrugCentral","snomedId":6020002,"regulator":"FDA","usPrevalence":null,"globalPrevalence":640000000,"prevalenceMethod":"curated","prevalenceSource":"BMC Public Health, 2025 (PMID:40993673)"}],"offLabel":[{"name":"Psoriasis","source":"DrugCentral","drugName":"BETAMETHASONE DIPROPIONATE","evidenceCount":496,"evidenceLevel":"strong"}],"pipeline":[]},"currentOwner":"Schering","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"alclometasone-dipropionate","brandName":"alclometasone dipropionate","genericName":"alclometasone dipropionate","approvalYear":"1982","relationship":"same-target"},{"drugId":"amcinonide","brandName":"amcinonide","genericName":"amcinonide","approvalYear":"1979","relationship":"same-target"},{"drugId":"auranofin","brandName":"auranofin","genericName":"auranofin","approvalYear":"1985","relationship":"same-target"},{"drugId":"beclometasone-dipropionate","brandName":"beclometasone dipropionate","genericName":"beclometasone dipropionate","approvalYear":"1976","relationship":"same-target"},{"drugId":"betamethasone","brandName":"betamethasone","genericName":"betamethasone","approvalYear":"1961","relationship":"same-target"},{"drugId":"betamethasone-acetate","brandName":"betamethasone acetate","genericName":"betamethasone acetate","approvalYear":"1965","relationship":"same-target"},{"drugId":"betamethasone-benzoate","brandName":"betamethasone benzoate","genericName":"betamethasone benzoate","approvalYear":"","relationship":"same-target"},{"drugId":"betamethasone-phosphate","brandName":"betamethasone phosphate","genericName":"betamethasone phosphate","approvalYear":"1965","relationship":"same-target"},{"drugId":"betamethasone-valerate","brandName":"betamethasone valerate","genericName":"betamethasone valerate","approvalYear":"1967","relationship":"same-target"},{"drugId":"budesonide","brandName":"budesonide","genericName":"budesonide","approvalYear":"1994","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT07391423","phase":"NA","title":"Assessing Psoriasis Treatment Outcomes","status":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-04","conditions":["Psoriasis"],"enrollment":15,"completionDate":"2029-03"},{"nctId":"NCT07357831","phase":"PHASE3","title":"A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-12-26","conditions":["Plaque Psoriasis"],"enrollment":537,"completionDate":"2026-12-17"},{"nctId":"NCT07337772","phase":"NA","title":"Comparing Different Doses of Corticosteroids in Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty","status":"RECRUITING","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2026-02-01","conditions":["Adrenal Cortex Hormones","Arthroplasty, Replacement, Knee","Anesthesia, Local"],"enrollment":120,"completionDate":"2028-11-01"},{"nctId":"NCT05114096","phase":"PHASE4","title":"Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)","status":"RECRUITING","sponsor":"McMaster University","startDate":"2023-07-20","conditions":["Preterm Birth","Premature Birth","Complication of Prematurity","Obstetric Labor, Premature","Pregnancy Complications"],"enrollment":3254,"completionDate":"2029-12-31"},{"nctId":"NCT05981118","phase":"PHASE2,PHASE3","title":"Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)","status":"ENROLLING_BY_INVITATION","sponsor":"Wake Forest University Health Sciences","startDate":"2024-07-15","conditions":["ICD10 Code L40.9 for Psoriasis"],"enrollment":40,"completionDate":"2026-12"},{"nctId":"NCT07256834","phase":"PHASE1,PHASE2","title":"Comparison of Efficacy of Betamethasone Gel With Lidocaine Gel in Prevention of Post Endotracheal Intubation Sore Throat.","status":"NOT_YET_RECRUITING","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2025-11-22","conditions":["Post Operative Sore Throat at 6hrs and 24hrs After Endotracheal Intubation"],"enrollment":60,"completionDate":"2025-12-06"},{"nctId":"NCT07242846","phase":"PHASE4","title":"EFFECT OF INTRAARTICULAR TRIAMCINOLONE HEXACETONIDE AND BETAMETHASONE ON INTRAOCULAR PRESSURE","status":"COMPLETED","sponsor":"Nigde Omer Halisdemir University","startDate":"2025-10-02","conditions":["Knee Osteoarthritis (Knee OA)","Intraocular Pressure"],"enrollment":80,"completionDate":"2025-11-10"},{"nctId":"NCT04207931","phase":"PHASE4","title":"Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2018-04-30","conditions":["Central Centrifugal Cicatricial Alopecia (CCCA)"],"enrollment":250,"completionDate":"2026-08"},{"nctId":"NCT05185258","phase":"PHASE4","title":"Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2022-02-16","conditions":["Psoriasis Vulgaris","Psoriasis","Skin Diseases","Skin Diseases, Papulosquamous","Skin and Connective Tissue Diseases"],"enrollment":12,"completionDate":"2026-07-15"},{"nctId":"NCT05811234","phase":"","title":"A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2023-06-13","conditions":["Plaque Psoriasis"],"enrollment":291,"completionDate":"2024-10-01"},{"nctId":"NCT05926895","phase":"NA","title":"Investigation of the Effect of Central Sensitization (CS) on Steroid Injection Response in Rotator Cuff Lesion","status":"COMPLETED","sponsor":"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey","startDate":"2023-06-02","conditions":["Central Sensitisation","Subacromial Impingement Syndrome"],"enrollment":44,"completionDate":"2024-12-30"},{"nctId":"NCT07002892","phase":"NA","title":"Effectiveness of Corticosteroid and 5% Dextrose Versus USG-guided Ozone Injections in Patients With Carpal Tunnel Syndrome: Three Blind Randomized Studies","status":"RECRUITING","sponsor":"Yunus Burak Bayır","startDate":"2025-01-01","conditions":["Carpal Tunnel Syndrome Treatment"],"enrollment":72,"completionDate":"2026-01-01"},{"nctId":"NCT06599086","phase":"NA","title":"Efficacy of Steroid Injection in Patients With Bifid Median Nerve Diagnosed Carpal Tunnel Syndrome","status":"RECRUITING","sponsor":"Yunus Burak Bayır","startDate":"2024-09-15","conditions":["Carpal Tunnel Syndrome"],"enrollment":40,"completionDate":"2025-09-14"},{"nctId":"NCT06332612","phase":"PHASE1,PHASE2","title":"Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial","status":"COMPLETED","sponsor":"Ziauddin University","startDate":"2024-08-12","conditions":["Oral Submucous Fibrosis"],"enrollment":30,"completionDate":"2025-01-06"},{"nctId":"NCT01195831","phase":"PHASE3","title":"Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-09","conditions":["Scalp Psoriasis"],"enrollment":244,"completionDate":"2011-03"},{"nctId":"NCT00875277","phase":"PHASE2","title":"A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2009-04","conditions":["Psoriasis Vulgaris"],"enrollment":24,"completionDate":"2009-07"},{"nctId":"NCT01422434","phase":"PHASE3","title":"LEO 90105 Ointment in Japanese Subjects With Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2011-07","conditions":["Psoriasis"],"enrollment":676,"completionDate":"2012-04"},{"nctId":"NCT00817219","phase":"PHASE2","title":"Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2009-07","conditions":["Psoriasis Vulgaris"],"enrollment":33,"completionDate":"2011-12"},{"nctId":"NCT01768013","phase":"PHASE1,PHASE2","title":"The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-07","conditions":["Psoriasis Vulgaris"],"enrollment":13,"completionDate":"2012-10"},{"nctId":"NCT01120223","phase":"PHASE2","title":"Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-05","conditions":["Scalp Psoriasis"],"enrollment":78,"completionDate":"2012-10"},{"nctId":"NCT01083758","phase":"PHASE2","title":"Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-04","conditions":["Scalp Psoriasis"],"enrollment":31,"completionDate":"2012-10"},{"nctId":"NCT02038569","phase":"PHASE2","title":"An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-01","conditions":["Psoriasis Vulgaris"],"enrollment":125,"completionDate":"2018-02-13"},{"nctId":"NCT03806790","phase":"PHASE3","title":"Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2019-01-24","conditions":["Psoriasis Vulgaris"],"enrollment":182,"completionDate":"2019-06-10"},{"nctId":"NCT01866163","phase":"PHASE3","title":"LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-06","conditions":["Psoriasis Vulgaris"],"enrollment":426,"completionDate":"2013-11"},{"nctId":"NCT01188928","phase":"PHASE3","title":"LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-09","conditions":["Psoriasis Vulgaris"],"enrollment":1152,"completionDate":"2011-03"},{"nctId":"NCT02132936","phase":"PHASE3","title":"LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-06","conditions":["Psoriasis Vulgaris"],"enrollment":504,"completionDate":"2015-02"},{"nctId":"NCT02310646","phase":"PHASE3","title":"Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-01","conditions":["Psoriasis Vulgaris"],"enrollment":219,"completionDate":"2015-07"},{"nctId":"NCT00670241","phase":"PHASE3","title":"Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2008-04","conditions":["Psoriasis Vulgaris"],"enrollment":458,"completionDate":"2009-04"},{"nctId":"NCT02668692","phase":"PHASE3","title":"LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-02","conditions":["Psoriasis Vulgaris"],"enrollment":213,"completionDate":"2016-06"},{"nctId":"NCT02518048","phase":"PHASE2","title":"A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-08","conditions":["Skin and Connective Tissue Diseases"],"enrollment":35,"completionDate":"2016-01"},{"nctId":"NCT01600222","phase":"PHASE2","title":"Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-05","conditions":["Psoriasis Vulgaris"],"enrollment":37,"completionDate":"2013-05"},{"nctId":"NCT01536886","phase":"PHASE2","title":"LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-05","conditions":["Psoriasis Vulgaris"],"enrollment":376,"completionDate":"2012-11"},{"nctId":"NCT01536938","phase":"PHASE2","title":"LEO 90100 in the Treatment of Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-05","conditions":["Psoriasis Vulgaris"],"enrollment":303,"completionDate":"2012-11"},{"nctId":"NCT01347255","phase":"PHASE2","title":"A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2011-05","conditions":["Psoriasis Vulgaris"],"enrollment":24,"completionDate":"2011-06"},{"nctId":"NCT05475808","phase":"PHASE4","title":"Comparison of the Efficacy of Different Treatment Methods in Patients With Carpal Tunnel Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abant Izzet Baysal University","startDate":"2022-08-01","conditions":["Carpal Tunnel Syndrome"],"enrollment":60,"completionDate":"2025-05-27"},{"nctId":"NCT05260125","phase":"PHASE4","title":"Comparison of the Efficacy of Ultrasound Guided vs Non-guided Suprascapular Nerve Block Treatment in Stroke Patients","status":"RECRUITING","sponsor":"Abant Izzet Baysal University","startDate":"2022-03-15","conditions":["Hemiplegia","Stroke"],"enrollment":50,"completionDate":"2025-03-30"},{"nctId":"NCT01837576","phase":"PHASE1","title":"An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-04","conditions":["Psoriasis Vulgaris"],"enrollment":24,"completionDate":"2013-06"},{"nctId":"NCT02376049","phase":"PHASE1","title":"A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-02","conditions":["Atopic Dermatitis"],"enrollment":30,"completionDate":"2015-07"},{"nctId":"NCT00216892","phase":"PHASE4","title":"Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2005-04","conditions":["Psoriasis Vulgaris"],"enrollment":1032,"completionDate":"2005-12"},{"nctId":"NCT02355639","phase":"PHASE1","title":"A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-01","conditions":["Skin and Connective Tissue Diseases"],"enrollment":16,"completionDate":"2015-04"},{"nctId":"NCT03898583","phase":"PHASE1","title":"Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2019-04-15","conditions":["Psoriasis Vulgaris"],"enrollment":15,"completionDate":"2019-10-29"},{"nctId":"NCT00243464","phase":"PHASE3","title":"Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2005-09","conditions":["Psoriasis of Scalp"],"enrollment":300,"completionDate":"2006-05"},{"nctId":"NCT02416258","phase":"PHASE2","title":"A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-04","conditions":["Skin and Connective Tissue Diseases"],"enrollment":50,"completionDate":"2015-06"},{"nctId":"NCT00216827","phase":"PHASE3","title":"Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2004-11","conditions":["Psoriasis of Scalp"],"enrollment":1485,"completionDate":"2005-09"},{"nctId":"NCT01946386","phase":"PHASE1","title":"A Vasoconstriction Study With LEO 90100","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-09","conditions":["Psoriasis Vulgaris"],"enrollment":35,"completionDate":"2013-10"},{"nctId":"NCT03442244","phase":"PHASE1","title":"Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-01-30","conditions":["Psoriasis Vulgaris"],"enrollment":20,"completionDate":"2018-02-20"},{"nctId":"NCT00216879","phase":"PHASE3","title":"Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2005-02","conditions":["Psoriasis of Scalp"],"enrollment":800,"completionDate":"2006-07"},{"nctId":"NCT01229098","phase":"PHASE2","title":"Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-10","conditions":["Psoriasis Vulgaris"],"enrollment":102,"completionDate":"2011-10"},{"nctId":"NCT00248456","phase":"PHASE4","title":"Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Ointment in Patients With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2005-10","conditions":["Psoriasis Vulgaris"],"enrollment":320,"completionDate":"2006-02"},{"nctId":"NCT00263718","phase":"PHASE2","title":"Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2005-12","conditions":["Psoriasis Vulgaris"],"enrollment":360,"completionDate":"2006-05"},{"nctId":"NCT00279162","phase":"PHASE3","title":"Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2005-12","conditions":["Psoriasis"],"enrollment":160,"completionDate":"2007-07"},{"nctId":"NCT00216840","phase":"PHASE3","title":"Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2004-12","conditions":["Psoriasis of Scalp"],"enrollment":1350,"completionDate":"2005-09"},{"nctId":"NCT02379793","phase":"PHASE1","title":"Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-03","conditions":["Skin and Connective Tissue Diseases"],"enrollment":33,"completionDate":"2015-04"},{"nctId":"NCT03476746","phase":"PHASE1","title":"Dermatopharmacokinetic Trial of LEO 90100 Foam","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-03-20","conditions":["Healthy"],"enrollment":58,"completionDate":"2018-07-01"},{"nctId":"NCT04227288","phase":"PHASE4","title":"A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-01","conditions":["Nail Psoriasis"],"enrollment":6,"completionDate":"2023-10-31"},{"nctId":"NCT05983445","phase":"PHASE3","title":"Safety & Efffficacy of Genakumab in Patients With Frequent Flares","status":"COMPLETED","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2023-01-11","conditions":["Acute Gout Arthritis"],"enrollment":313,"completionDate":"2024-04-03"},{"nctId":"NCT03308799","phase":"PHASE3","title":"A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2017-10-03","conditions":["Psoriasis Vulgaris"],"enrollment":794,"completionDate":"2018-06-08"},{"nctId":"NCT05882903","phase":"PHASE2","title":"The Effect of Intra-sinus Application of Betamethasone Dipropionate Nasal Cream on Patients with Chronic Rhinosinusitis Post Functional Endoscopic Sinus Surgery (FESS)","status":"RECRUITING","sponsor":"Oticara Australia PTY LTD","startDate":"2023-08-17","conditions":["Chronic Rhinosinusitis (Diagnosis)"],"enrollment":24,"completionDate":"2025-06-01"},{"nctId":"NCT06600815","phase":"NA","title":"Analgesic Efficacy of Preemptive Stepwise Infiltration Anesthesia for Perioperative Analgesia After TKA","status":"RECRUITING","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2024-09-30","conditions":["Total Knee Arthroplasty","Pain Management"],"enrollment":110,"completionDate":"2025-12"},{"nctId":"NCT05139875","phase":"PHASE4","title":"Comparing Intra-articular Betamethasone (Diprospan) and Triamcinolone Acetonide Injection in Knee Osteoarthritis","status":"COMPLETED","sponsor":"Thammasat University","startDate":"2022-01-01","conditions":["Knee Osteoarthritis"],"enrollment":105,"completionDate":"2024-04-30"},{"nctId":"NCT05220293","phase":"PHASE1,PHASE2","title":"Treatment of Eosinophilic Chronic Rhinosinusitis Utilizing Betamethasone Dipropionate Nasal Cream","status":"TERMINATED","sponsor":"Oticara Australia PTY LTD","startDate":"2022-02-23","conditions":["Chronic Rhinosinusitis (Diagnosis)"],"enrollment":2,"completionDate":"2023-12-30"},{"nctId":"NCT06329258","phase":"PHASE4","title":"Combination of Sotyktu and Enstilar for Plaque Psoriasis","status":"COMPLETED","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2022-12-06","conditions":["Psoriasis"],"enrollment":30,"completionDate":"2023-11-13"},{"nctId":"NCT02070965","phase":"PHASE2","title":"DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Primus Pharmaceuticals","startDate":"2014-01","conditions":["Plaque Psoriasis"],"enrollment":75,"completionDate":"2014-10"},{"nctId":"NCT02527421","phase":"PHASE3","title":"DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis","status":"TERMINATED","sponsor":"Primus Pharmaceuticals","startDate":"2015-08-19","conditions":["Plaque Psoriasis"],"enrollment":3,"completionDate":"2019-03-30"},{"nctId":"NCT02749799","phase":"PHASE4","title":"Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"Primus Pharmaceuticals","startDate":"2016-02","conditions":["Plaque Psoriasis"],"enrollment":45,"completionDate":"2016-08"},{"nctId":"NCT04976816","phase":"PHASE2,PHASE3","title":"Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease","status":"COMPLETED","sponsor":"Assiut University","startDate":"2021-12-01","conditions":["Thyroid Eye Disease"],"enrollment":92,"completionDate":"2023-10-30"},{"nctId":"NCT05571046","phase":"PHASE4","title":"Glucocorticoid Injection in Patients With Lumbar Radicular Pain","status":"COMPLETED","sponsor":"Cukurova University","startDate":"2022-06-01","conditions":["Radiculopathy Lumbar"],"enrollment":60,"completionDate":"2023-10-26"},{"nctId":"NCT05956171","phase":"NA","title":"The Effects of Two Different Treatment Protocols on Shoulder Function, Quality of Life, and Ultrasound Parameters in Patients With Frozen Shoulder","status":"UNKNOWN","sponsor":"Istanbul University","startDate":"2023-10-01","conditions":["Frozen Shoulder","Shoulder Capsulitis","Shoulder Pain"],"enrollment":50,"completionDate":"2024-03"},{"nctId":"NCT06011083","phase":"NA","title":"Topical Calcipotriol /Betamethasone Ointment in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Assiut University","startDate":"2022-08-01","conditions":["Psoriasis Vulgaris","Fractional CO2 Laser"],"enrollment":40,"completionDate":"2023-08-01"},{"nctId":"NCT04494529","phase":"PHASE3","title":"Single Dose Antenatal Corticosteroids (SNACS) for Women at Risk of Preterm Birth","status":"COMPLETED","sponsor":"McMaster University","startDate":"2021-03-01","conditions":["Preterm Birth","Complication of Prematurity","Obstetric Labor, Premature","Obstetric Labor Complications","Pregnancy Complications"],"enrollment":30,"completionDate":"2021-08-31"},{"nctId":"NCT04876859","phase":"PHASE3","title":"Comparative Study Between Steroid Plus Anesthetic Block and CRF in Participants With Hip Osteoarthritis","status":"SUSPENDED","sponsor":"University of Brasilia","startDate":"2021-06-08","conditions":["Hip Osteoarthritis","Chronic Pain"],"enrollment":36,"completionDate":"2024-11-30"},{"nctId":"NCT05556122","phase":"NA","title":"Efficacy of Compound Betamethasone Injection Combined With Ropivacaine in Ultrasound-guided Intercostal Nerve Block for Chronic Post-thoracotomy Pain","status":"UNKNOWN","sponsor":"Affiliated Hospital of Nantong University","startDate":"2022-07-04","conditions":["Nerve Block"],"enrollment":100,"completionDate":"2022-12-30"},{"nctId":"NCT05504759","phase":"NA","title":"Efficacy of Dry Needling in the Treatment of Lateral Epicondylitis","status":"UNKNOWN","sponsor":"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey","startDate":"2021-02-02","conditions":["Lateral Epicondylitis"],"enrollment":60,"completionDate":"2023-08-02"},{"nctId":"NCT00437255","phase":"PHASE4","title":"Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-08","conditions":["Plaque Psoriasis"],"enrollment":122,"completionDate":"2007-06"},{"nctId":"NCT05303766","phase":"NA","title":"Radiofrequency Ablation in the Pain Management of Knee Osteoarthritis","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-04","conditions":["Knee Osteoarthritis"],"enrollment":150,"completionDate":"2023-03"},{"nctId":"NCT05266391","phase":"","title":"Injection Technique in Subacromial Impingement Syndrome","status":"COMPLETED","sponsor":"Istanbul Physical Medicine Rehabilitation Training and Research Hospital","startDate":"2018-06-01","conditions":["Subacromial Impingement Syndrome"],"enrollment":40,"completionDate":"2018-09-01"},{"nctId":"NCT04580537","phase":"PHASE2","title":"Assessing the Efficacy of Image-guided Laser-assisted Enstilar® Delivery for Treatment of Psoriatic Nails","status":"COMPLETED","sponsor":"Bispebjerg Hospital","startDate":"2020-10-02","conditions":["Nail Psoriasis"],"enrollment":11,"completionDate":"2021-06-01"},{"nctId":"NCT05175001","phase":"PHASE4","title":"Efficacy of Compound Betamethasone Injection Combined With Ropivacaine in Ultrasound-guided Thoracic Paravertebral Nerve Block for Chronic Post-thoracotomy Pain","status":"UNKNOWN","sponsor":"Affiliated Hospital of Nantong University","startDate":"2021-05-01","conditions":["Chronic Pain"],"enrollment":100,"completionDate":"2023-01-30"},{"nctId":"NCT00820950","phase":"PHASE2","title":"A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2007-05-31","conditions":["Psoriasis"],"enrollment":29,"completionDate":"2009-04-30"},{"nctId":"NCT00800293","phase":"","title":"Randomized Study to Compare the Bioavailability of Two Augmented Betamethasone Dipropionate 0.05% Topical Creams","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2002-12","conditions":["Healthy"],"enrollment":116,"completionDate":"2003-01"},{"nctId":"NCT02582177","phase":"PHASE3","title":"Effectiveness Study of Ketoconazole and Betamethasone to Treat Fungal Infection and Dermatophytosis","status":"COMPLETED","sponsor":"Ache Laboratorios Farmaceuticos S.A.","startDate":"2019-06-11","conditions":["Tinea"],"enrollment":125,"completionDate":"2020-03-24"},{"nctId":"NCT04380597","phase":"","title":"Observational Study in Patients With Nail Psoriasis Treated With Enstilar® to Assess the Severity Change and the Quality of Life","status":"COMPLETED","sponsor":"Angeles Florez","startDate":"2019-03-26","conditions":["Nail Psoriasis"],"enrollment":10,"completionDate":"2021-07-30"},{"nctId":"NCT02935582","phase":"","title":"PSOREAL - Managing PSOriasis in the REAL World","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-01","conditions":["Psoriasis Vulgaris"],"enrollment":1214,"completionDate":"2020-12-30"},{"nctId":"NCT04444726","phase":"NA","title":"Phototherpy Versus Tapwater Iontophoresis for Management of Atopic Dermatitis in Children.","status":"COMPLETED","sponsor":"Cairo University","startDate":"2019-01-20","conditions":["Atopic Dermatitis"],"enrollment":60,"completionDate":"2020-11-21"},{"nctId":"NCT04887844","phase":"NA","title":"Efficacy of Corticosteroid and Local Anesthetic Injections Patients With Concomitant Pes Anserine Bursitis","status":"COMPLETED","sponsor":"Abant Izzet Baysal University","startDate":"2019-03-01","conditions":["Osteoarthritis Knees Both"],"enrollment":102,"completionDate":"2020-03-15"},{"nctId":"NCT04114097","phase":"PHASE4","title":"The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover","status":"COMPLETED","sponsor":"Jacob Thyssen","startDate":"2019-08-22","conditions":["Atopic Dermatitis","Atopic Eczema"],"enrollment":36,"completionDate":"2021-03-15"},{"nctId":"NCT03819218","phase":"PHASE2","title":"A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects","status":"TERMINATED","sponsor":"MC2 Therapeutics","startDate":"2018-12-27","conditions":["Psoriasis Vulgaris"],"enrollment":7,"completionDate":"2020-12-11"},{"nctId":"NCT03506477","phase":"PHASE4","title":"Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2018-05-21","conditions":["Plaque Psoriasis","Psoriasis"],"enrollment":25,"completionDate":"2019-09-25"},{"nctId":"NCT03802344","phase":"PHASE3","title":"This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2018-12-12","conditions":["Psoriasis Vulgaris"],"enrollment":498,"completionDate":"2019-10-02"},{"nctId":"NCT03766997","phase":"PHASE4","title":"Local Steroid Treatment for Idiopathic Granulomatous Mastitis (LSTIGM)","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-02-19","conditions":["Granulomatous Mastitis"],"enrollment":100,"completionDate":"2022-01"},{"nctId":"NCT04433377","phase":"NA","title":"Comparison Suprascapular Nerve Block and Subacromial Injection in Hemiplegic Shoulder Pain","status":"COMPLETED","sponsor":"Istanbul Physical Medicine Rehabilitation Training and Research Hospital","startDate":"2020-05-28","conditions":["Hemiplegia","Pain"],"enrollment":50,"completionDate":"2020-10-01"},{"nctId":"NCT04555707","phase":"PHASE4","title":"The Maintenance Effect of Enstilar Foam in Combination With Otezla","status":"UNKNOWN","sponsor":"Derm Research, PLLC","startDate":"2020-06-24","conditions":["Psoriasis"],"enrollment":30,"completionDate":"2021-09-30"},{"nctId":"NCT03848871","phase":"PHASE4","title":"The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients","status":"COMPLETED","sponsor":"Derm Research, PLLC","startDate":"2017-12-12","conditions":["Plaque Psoriasis"],"enrollment":20,"completionDate":"2018-12-10"},{"nctId":"NCT03731091","phase":"PHASE3","title":"To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2018-10-31","conditions":["Psoriasis Vulgaris"],"enrollment":494,"completionDate":"2020-03-17"},{"nctId":"NCT02916940","phase":"PHASE2","title":"Injection of Corticoids for the Treatment of Acute Sprains of the Proximal Interphalangeal Joints of the Fingers.","status":"COMPLETED","sponsor":"Brugmann University Hospital","startDate":"2016-11-16","conditions":["Sprain"],"enrollment":60,"completionDate":"2020-02-11"},{"nctId":"NCT04372277","phase":"PHASE4","title":"Taltz in Combination With Enstilar for Psoriasis","status":"RECRUITING","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2020-04-28","conditions":["Psoriasis"],"enrollment":25,"completionDate":"2021-03-30"},{"nctId":"NCT03899064","phase":"PHASE1","title":"Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2019-02-13","conditions":["Photoallergy"],"enrollment":58,"completionDate":"2019-04-05"},{"nctId":"NCT03892564","phase":"PHASE1","title":"Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2019-02-27","conditions":["Phototoxicity"],"enrollment":35,"completionDate":"2019-03-09"},{"nctId":"NCT03758365","phase":"PHASE1","title":"Evaluation of the Vasoconstriction Properties of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2018-11-05","conditions":["Vasoconstriction"],"enrollment":36,"completionDate":"2018-11-23"},{"nctId":"NCT03462927","phase":"PHASE2","title":"A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2018-02-08","conditions":["Psoriasis Vulgaris"],"enrollment":63,"completionDate":"2018-08-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Topical","formulation":"Aerosol, Cream","formulations":[{"form":"AEROSOL, FOAM","route":"TOPICAL","productName":"ENSTILAR"},{"form":"CREAM","route":"TOPICAL","productName":"BETAMETHASONE CLOTRIMAZOLE"},{"form":"CREAM","route":"TOPICAL","productName":"BETAMETHASONE DIPROPIONATE"},{"form":"CREAM","route":"TOPICAL","productName":"Betamethasone Dipropionate"},{"form":"CREAM","route":"TOPICAL","productName":"Betamethasone dipropionate"},{"form":"CREAM","route":"TOPICAL","productName":"CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE"},{"form":"CREAM","route":"TOPICAL","productName":"Clotrimazole and Betamethasone Dipropionate"},{"form":"CREAM","route":"TOPICAL","productName":"Betamethasone Dipropionate"},{"form":"CREAM","route":"TOPICAL","productName":"Clotrimazole and Betamethasone Dipropionate"},{"form":"CREAM","route":"TOPICAL","productName":"Lotrisone"},{"form":"CREAM","route":"TOPICAL","productName":"Wynzora"},{"form":"CREAM","route":"TOPICAL","productName":"BETAMETHASONE  DIPROPIONATE 0.05% / NIACINAMIDE 4%"},{"form":"CREAM","route":"TOPICAL","productName":"DR. THROWERS BETA"},{"form":"CREAM","route":"TOPICAL","productName":"DR. THROWERS PBC NO. 1"},{"form":"CREAM, AUGMENTED","route":"TOPICAL","productName":"Betamethasone Dipropionate"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000179052","MMSL":"10006","NDDF":"002168","UNII":"826Y60901U","VUID":"4018642","CHEBI":"CHEBI:3077","VANDF":"4018642","INN_ID":"1045","RXNORM":"1514","UMLSCUI":"C0053523","chemblId":"CHEMBL3138708","ChEMBL_ID":"CHEMBL1200384","KEGG_DRUG":"D01637","DRUGBANK_ID":"DB00443","PUBCHEM_CID":"21800","SNOMEDCT_US":"116571008","MESH_DESCRIPTOR_UI":"D001623","MESH_SUPPLEMENTAL_RECORD_UI":"C011175"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1975-","companyName":"Schering","relationship":"Original Developer"}],"publicationCount":700,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"originalDeveloper":"Schering","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":21,"_genericFilersChecked":true,"genericManufacturerList":["Actavis Mid Atlantic","Alpharma Us Pharms","Aurobindo Pharma Ltd","Chartwell Molecular","Cosette","Encube","Fougera Pharms","Fougera Pharms Inc","Glenmark Pharms Inc","Hikma","Lupin Ltd","Padagis Israel","Padagis Us","Perrigo New York","Savage Labs","Shree Hari Intl","Sun Pharma Canada","Teva","Tp Anda Holdings","Zydus Lifesciences","Zydus Pharms"],"status":"approved","companyName":"Schering","companyId":"merck","modality":"Small molecule","firstApprovalDate":"1975","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2009-09-28T00:00:00.000Z","mah":"PADAGIS ISRAEL","brand_name_local":null,"application_number":"ANDA076592"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-12-12T00:00:00.000Z","mah":"PADAGIS ISRAEL","brand_name_local":null,"application_number":"ANDA200174"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-03-08T00:00:00.000Z","mah":"LEO PHARMA AS","brand_name_local":null,"application_number":"NDA207589"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-12-18T00:00:00.000Z","mah":"LUPIN LTD","brand_name_local":null,"application_number":"ANDA209106"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-06-09T00:00:00.000Z","mah":"FOUGERA PHARMS","brand_name_local":null,"application_number":"ANDA075373"},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"9775851","territory":"US","patent_type":"Formulation","expiry_date":"2030-08-31T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9364485","territory":"US","patent_type":"Formulation","expiry_date":"2030-08-31T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9655907","territory":"US","patent_type":"Formulation","expiry_date":"2030-08-31T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10179137","territory":"US","patent_type":"Formulation","expiry_date":"2030-08-31T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9433630","territory":"US","patent_type":"Formulation","expiry_date":"2030-08-31T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9877974","territory":"US","patent_type":"Formulation","expiry_date":"2030-08-31T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9439911","territory":"US","patent_type":"Formulation","expiry_date":"2030-08-31T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:43:58.890147+00:00","fieldsConflicting":3,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}